Gilead Sciences presented new results from its Phase 2/3 CAPELLA study focused on its investigational, long-acting HIV-1 capsid inhibitor, lenacapavir. The trial, which involved heavily treatment-experienced people with multi-drug resistant HIV-1 infection, showed that lenacapavir had substantial virologic suppression for 26 weeks. In November, the company had announced that 88% of lenacapavir recipients in the…
Abbott researchers help discover a clue to an HIV cure
Abbott announced today that a team including its scientists has uncovered a rare group of Democratic Republic of Congo residents who are HIV positive but have almost nonexistent viral loads without using antiretroviral treatments. This group of “HIV elite controllers” opens up a new area for researchers to discover biological trends that could inform the…